Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

NCT04779892 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT04779892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04779892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 1
Overall status
Completed
Start date
February 1, 2020
Completion date
June 15, 2020
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis